Morfine Sulphate Aurobindo (Morphine Sulfate)

Morphine sulfate binds to μ‑opioid receptors in the brain and spinal cord, inhibiting the release of pain‑transmitting neurotransmitters and reducing neuronal excitability. This action modifies the perception of pain and produces a strong analgesic effect.

The appropriate dose of morphine sulfate is individualized by the prescribing clinician based on the patient’s pain severity, prior opioid exposure, renal and hepatic function, and overall clinical condition. Dosage regimens are not standardized and must follow a qualified prescriber’s order.

Morphine sulfate is classified as Pregnancy Category C, indicating that risk to the fetus cannot be ruled out and it should be used only if the potential benefit justifies the potential risk. It is excreted in breast milk; therefore, caution is advised when prescribing to nursing mothers.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Morphine sulfate is a benchmark opioid with well‑characterized efficacy and safety profiles. Compared with newer synthetic opioids, it has a longer history of clinical use, predictable pharmacokinetics, and is often less expensive, though individual response and side‑effect profiles may vary.

Morfine Sulphate Aurobindo should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not store in damp or excessively hot environments.

The product is formulated for oral administration. It is taken by mouth with or without food as directed by a healthcare professional. Swallow tablets or capsules whole; do not crush or chew unless specifically instructed.

The most serious risks include respiratory depression, severe hypotension, profound sedation, dependence or addiction, and rare but life‑threatening allergic reactions. Patients should be monitored closely, especially during dose initiation or when combined with other central nervous system depressants.

Morphine sulfate is contraindicated in patients with known hypersensitivity to morphine or other opioids, those with significant respiratory depression, acute or severe asthma, and in individuals who have taken monoamine oxidase inhibitors within the past 14 days. Caution is also required for patients with uncontrolled head injury or increased intracranial pressure.